Astellas Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Astellas Pharma sits in the top decile of US sponsors by registered trial count (#179 of 15,742 sponsors by registered trial count).
Astellas Pharma: 165 sponsored US clinical trials, 2 recruiting.
Astellas Pharma sponsors 165 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 143 completed. 47 of these trials are in Phase 3-4 (later-stage) and 113 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Candidemia, with 4 trials.
Top-decile sponsor footprint
Astellas Pharma ranks in the top decile of sponsors by registered trial count (#179 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
143 of 162 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
165 total, page 1 of 4
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204
A Study of ASP3082 in Adults With Advanced Solid Tumors
NCT05382559
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
NCT06364696
A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery
NCT05457842
A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy
NCT04641962
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)
NCT04184882
A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery
NCT04238481
Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery
NCT03941483
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
NCT03219333
An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors
NCT02038673
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
NCT01554696
A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)
NCT01533428
Drug Interaction Study of Isavuconazole and Tacrolimus
NCT01535547
A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients
NCT01442337
Drug Interaction Study of Isavuconazole and Cyclosporine
NCT01494597
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
NCT01534052
A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation
NCT01484964
A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K
NCT01486017
A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy
NCT01371994
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
NCT01409135
A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil
NCT01406145
Drug Interaction Study of Isavuconazole and Midazolam
NCT01406171
A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation
NCT01406158
A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
NCT01334918
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
NCT01221077
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
NCT01288911
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
NCT01186861
A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept
NCT01339481
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
NCT01101906
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
NCT01284192
A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation
NCT01279538
A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects
NCT01284309
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
NCT01228760
A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects
NCT01232413
A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer
NCT01114230
A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus
NCT01190670
A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)
NCT01099345
A Study to Assess Drug Interaction of ASP015K and Midazolam
NCT01182077
A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females
NCT01199523
A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941
NCT01187186
A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus
NCT01117584
A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug
NCT01124747
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
NCT01096862
A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus
NCT01071850
A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects
NCT01104532
A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis
NCT01754805
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
NCT01093534
A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
NCT00924989
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
NCT01038804
A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male Subjects
NCT01406132
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 59 |
| Phase 2 | 54 |
| Phase 3 | 28 |
| Phase 4 | 19 |
Therapeutic Areas
What is open in the Astellas Pharma pipeline
2 recruiting of 165 indexed (1% open); 143 completed (87%).
Phase mix: 47 late (III/IV) vs 113 early (I/II) (early-phase heavy).
Top condition: Candidemia (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Astellas Pharma: open-pipeline peers nationwide
Peers matched on 165 registered trials and 1% open enrollment, not the therapeutic-area sidebar.
Astellas Pharma sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 165 trials (± recruiting share)
- Teva Branded Pharmaceutical Products R&D · 167 trials · 4% recruiting
- Wyeth is now a wholly owned subsidiary of Pfizer · 167 trials · 0% recruiting
- Temple University · 163 trials · 13% recruiting
- Tufts University · 163 trials · 6% recruiting
Sponsors near 1% open enrollment (± trial volume)
- University of New Mexico · 1% recruiting · 168 trials
- Abbott Nutrition · 1% recruiting · 89 trials
- Baxalta now part of Shire · 1% recruiting · 74 trials
- Power Life Sciences · 2% recruiting · 62 trials
Related
What to do with this Astellas Pharma page
165 registered trials is a research-attention snapshot, not an endorsement of Astellas Pharma or any single study.
- 2 of Astellas Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Candidemia is the condition Astellas Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Candidemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Astellas Pharma pipeline card: 165 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.